Intravenous and Inhaled Antimicrobials at Home in Cystic Fibrosis Patients

被引:1
|
作者
Thigpen, Jim [1 ]
Odle, Brian [1 ]
机构
[1] East Tennessee State Univ, Johnson City, TN USA
关键词
cystic fibrosis; antimicrobial therapy; intravenous antibiotics; aerosolized antibiotics; home health; Pseudomonas aeruginosa; Staphylococcus aureus;
D O I
10.1177/1084822313501322
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The primary clinical characteristics of cystic fibrosis (CF) are malnutrition caused by malabsorption secondary to pancreatic insufficiency, chronic pulmonary infections, and male infertility. The major cause of morbidity and mortality are bronchiectasis and obstructive pulmonary disease. Lung disease in CF is manifested by this chronic lung disease progression, with intermittent episodes of acute worsening of symptoms called pulmonary exacerbations. Once the patient has stabilized, and if suitable care can be arranged, these interventions are often transitioned to the home. This review summarizes important points pertinent to the use of intravenous and inhaled antimicrobials that may be encountered by prescribers, nurses, technicians, and case managers in the home health setting. Appropriate dosing, indications, adverse drug reactions, monitoring parameters, and practicality of both intravenous and inhaled antimicrobials are discussed.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 50 条
  • [41] Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis
    Elborn, J. Stuart
    Flume, Patrick A.
    Van Devanter, Donald R.
    Procaccianti, Claudio
    FUTURE MICROBIOLOGY, 2021, 16 (14) : 1087 - 1104
  • [42] Inhaled mannitol for the treatment of cystic fibrosis
    Hurt, Katharine
    Bilton, Diana
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2012, 6 (01) : 19 - 26
  • [43] Inhaled Biologicals for the Treatment of Cystic Fibrosis
    Sala, Valentina
    Murabito, Alessandra
    Ghigo, Alessandra
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2019, 13 (01) : 19 - 26
  • [44] Home intravenous antibiotic therapy in children with cystic fibrosis: clinical outcome, quality of life and economic benefit
    Chrysochoou, E. A.
    Hatziagorou, E.
    Kirvassilis, F.
    Tsanakas, J.
    HIPPOKRATIA, 2016, 20 (04) : 279 - 283
  • [45] Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis
    Conway, SP
    Pond, HN
    Watson, A
    Etherington, C
    Robey, HL
    Goldman, MH
    THORAX, 1997, 52 (11) : 987 - 993
  • [46] Tolerance of two inhaled hypertonic saline solutions in patients with cystic fibrosis
    Maiz Carro, Luis
    Lamas Ferreiro, Adelaida
    de Valbuena Maiz, Marta Ruiz
    Wagner Struwing, Carolin
    Gabilondo Alvarez, Gustavo
    Suarez Cortina, Lucrecia
    MEDICINA CLINICA, 2012, 138 (02): : 57 - 59
  • [47] Inhaled colistin following lung transplantation in colonised cystic fibrosis patients
    Suhling, Hendrik
    Rademacher, Jessica
    Greer, Mark
    Haverich, Axel
    Warnecke, Gregor
    Gottlieb, Jens
    Welte, Tobias
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (02) : 542 - 544
  • [48] Home intravenous antibiotic treatment for acute pulmonary exacerbations in cystic fibrosis - Is it good for the patient?
    Sequeiros, Iara Maria
    Jarad, Nabil A.
    ANNALS OF THORACIC MEDICINE, 2009, 4 (03) : 111 - 114
  • [49] Administration of aerosolized antibiotics in cystic fibrosis patients
    Moss, RB
    CHEST, 2001, 120 (03) : 107S - 113S
  • [50] Inhaled medications in cystic fibrosis beyond antibiotics
    Sepe, Angela
    Villella, Valeria R.
    Cimbalo, Chiara
    Castaldo, Alice
    Nunziata, Francesco
    Corcione, Adele
    Bona, Gianni
    Maiuri, Luigi
    Raia, Valeria
    MINERVA PEDIATRICA, 2019, 71 (04) : 371 - 375